Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
BENGALURU, India, Feb. 8, 2024 /PRNewswire/ — Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE
Read MoreBENGALURU, India, Feb. 8, 2024 /PRNewswire/ — Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE
Read MoreCompletes the multi-billion-dollar, value accretive transaction in part-equity and part-cash, including: Upfront cash payment of USD 2 billion Issuance of
Read MoreImmediately Accretive Combination Creates a Unique Global, Vertically Integrated Biosimilars Leader BENGALURU, India, Feb. 28, 2022 /PRNewswire/ — Biocon Biologics
Read More